Cell Genesys Inc.
Symbol:
CEGE
Exchange:
Nasdaq
Industry:
Healthcare
Products:
Drugs
Company Website: Click Here
Company Info: Click Here
Quote and News: Click Here
Profiled Price:
$0.33
(September 11)
Company Snapshot:
Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of nervous system growth (neurotrophic) factors for the treatment of neurodegenerative and retinal disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is currently in a multi-center, controlled Phase 2 study for the treatment of Alzheimer's disease, and CERE-120 (AAV2-Neurturin) for Parkinson's disease. CERE-135 and CERE-140 are in preclinical development for ALS (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001.
|
